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to previous treatment may not reap the beneﬁt of survival improve-
ment because they were already in a terminal stage at the time of stent 
placement. Interventional pulmonologists should be aware of the dis-
couraging prognosis and the risk of impediments for terminal patients, 
especially in cases of multiple stent placements. 
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Early detection and intervention for central airway cancers: 10 
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Background: Lung cancer accounts for more deaths than breast, pros-
tate and colon cancers combined. Prognosis and survival depend on the 
stage of disease, and since more than two thirds of patients with lung 
cancer have mediastinal lymph node or distant metastases at presenta-
tion, it is not surprising that cure rate remains dismal at 15%.
Aim: To determine if early detection and intervention for central air-
way lung cancer could impact outcome of patients at risk.
Methods: All current or former smokers with ≥1 aerodigestive cancers 
were recruited for the program beginning January 1996 to December 
2005 and prospectively followed till December 2006. Autoﬂuores-
cence bronchoscopy was performed with LIFE® (Xilix, BC, Richmond 
Canada) every 3-6 months, and where indicated, bronchoscopic treat-
ment was applied as an alternative to surgery or to enable less exten-
sive resection whenever feasible. Values are presented as median and 
range, and lung cancer related mortality is calculated by Kaplan Meier 
method.
Results: There were 228 individuals, 190 males with median age 69 
years (range, 62-75). They smoked 40 median pack years (range, 34-
50), and 70% had COPD with median FEV1 % predicted 53% (range, 
39-70). Follow-up was 40 months (range, 22-79), and the indications 
were: surveillance after lung cancer surgery in 94 patients (41%); 
previous ENT cancer in 32 (14%); suspected occult lung cancer in 92 
(41%); and known lung cancer in 10 (4%). There were 111 patients 
with one lung cancer, and 99 with 2 or more lung cancers. A total of 
217 new lung cancers were diagnosed: AF detected 181 and 36 by CT. 
Of the 92 patients with intraluminal squamous cell cancers (ISCC), 12 
(13%) underwent surgery with one requiring post-operative radio-
therapy (RT), 10 (11%) had RT alone and one (1%) received concurrent 
chemoradiotherapy. The remaining 69 patients (75%) had their multiple 
ISCC treated with endobronchial electrosurgery or cryotherapy. At the 
end of our study period, 123 individuals (54%) were alive, and 105 
(46%) deceased. Lung cancer-related mortality (Fig 1) was 21% (6.3%/ 
year) and the all cause mortality was 46%. 
Conclusions: Our results validate efforts towards early detection and 
intervention for this high risk group with ≥ 1 cancers. Bronchoscopic 
treatment could emerge as an effective alternative to surgery for early 
detected ISCC. 
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Background: The bronchial mucosa is the tissue ﬁrst exposed to dif-
ferent cancerogenes including tobacco smoke. Pathologic changes in 
the mucosa evolve from basal cell hyperplasia to epithelial dysplasia 
and cancer in situ. This process causes subtle changes in chemical 
composition and blood supply of mucosa and thickness of the basal 
membrane. This is why the processing of autoﬂuorescent signal from 
the bronchial mucosal surface is gaining increasing interest recently. 
Signiﬁcant weakness of commercial autoﬂuorescence systems is low 
speciﬁcity caused by decreased ﬂuorescence of the mucosa changed by 
chronic inﬂammation or other non-malignant endobronchial conditions. 
Methods: In order to increase speciﬁcity of the auto ﬂuorescent device 
we have tested system utilizing spectroscopic point monitoring of sus-
picious endobronchial locations. Every AFB positive location has been 
measured by this system and than visualized by NBI system. Evaluated 
group consisted of 30 patients with autoﬂuorescence positive endobron-
chial locations. 
Results and Conclusion: We have picked up some typical differences 
in autoﬂuorescence spectra’s between malignant and non-malignant 
tissues which are shown in graphs. We have also found that NBI tissue 
characteristics are very useful in discriminating between endobronchial 
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pathologies. Of 30 AF positive lesions we were able to deﬁne the sub-
group of 19 locations with speciﬁc spectroscopy pattern corresponding 
wit non-malignant histology. NBI bronchoscopy is not simple to inter-
pret but gives promising results in discrimination between malignant 
and benign endobronchial tissue. 
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Background: EBUS-TBNA was reported to have higher diagnostic ac-
curacy in lymph node (LN) staging of lung cancer compared to CT and 
PET. We conducted a prospective study to compare EBUS-TBNA with 
PET/CT in mediastinal LN staging, especially focused on histologic 
types of NSCLC. 
Methods: EBUS-TBNA was performed in 73 potentially operable 
NSCLC patients (pts) (M/F 60/13, median age 64 yrs). Chest CT and 
PET/CT were done before EBUS-TBNA. In case mediastinal LN me-
tastasis was not proved by EBUS-TBNA, surgery was performed. 
Results: Out of 73 pts, 34 had adenocarcinoma (ADC) and 32 had 
squamous cell ca (SCC)(large cell ca n=4, non-small cell ca unspeci-
ﬁed, n=3). One hundred twenty-six mediastinal LNs (2R = 6, 2L=1, 
4R=44, 4L=26, 7N=49) were sampled by EBUS-TBNA in 73 pts. 
EBUS-TBNA demonstrated metastasis in 34 LN stations in 23pts 
and missed 1 N2(+) patient (station 7, SCC). Overall, EBUS-TBNA 
showed higher diagnostic accuracy than PET/CT in mediastinal LN 
staging (Table, p=0.0075). EBUS-TBNA demonstrated LN metastasis 
in 3 PET (-) patients. All 3 pts had ADC. In ADC, positive predictive 
value (PPV) and negative predictive value (NPV) of PET/CT were 
81.3% and 83.3% respectively. In SCC, PPV of PET/CT was very low 
(33.3%) and NPV was high (94.1%). 
Conclusion: EBUS-TBNA is useful in mediastinal LN staging espe-
cially for the pts with mediastinal PET (-) adenocarcinoma and PET (+) 
NSCLC.
  Sensitivity Speciﬁcity PPV NPV Accuracy
Total, n=73 PET/CT 83.3(20/24) 69.3(34/49) 57.1(20/35) 89.5(34/38) 74.0(54/73)
 EBUS-TBNA 95.8(23/24) 100(49/49) 100(23/23) 98.0(49/50) 98.6(72/73)
ADC, n=34 PET/CT 81.3(13/16) 83.3(15/18) 81.3(13/16) 83.3(15/18) 82.4(28/34)
 EBUS-TBNA 100(16/16) 100(18/18) 100(16/16) 100(18/18) 100(34/34)
SCC, n=32 PET/CT 83.3(5/6) 61.5(16/26) 33.3(5/15) 94.1(16/17) 65.6(21/32)
 EBUS-TBNA 83.3(5/6) 100(26/26) 100(5/5) 96.3(26/27) 96.9(31/32)
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Backgroud: We had previously developed the possibility of use of a 
photodynamic diagnosis (PDD) system using a tumor-selective photo-
sensitizer and laser irradiation for the early detection and photodynamic 
therapy (PDT) of centrally located early lung cancers. Recently, we 
established the autoﬂuorescence diagnosis system integrated into a 
videoendoscope (SAFE-3000) as a very useful technique for the early 
diagnosis of lung cancer. 
Patients and Methods: Thirty-four patients (45 lesions) with cen-
trally located early lung cancer (Squamous cell carcinoma, carcinoma 
in situ, TisN0M0, stage 0) received PDT using the second-generation 
photosensitizer, talaporﬁn sodium (NPe6), and a diode laser (664 nm). 
Just before the PDT, we deﬁned the tumor margin accurately using the 
novel PDD system SAFE-3000 with NPe6 and a diode laser (408 nm).
Results: Red ﬂuorescence emitted from the tumor by excitation of the 
photosensitizer by the diode laser (408 nm) from SAFE-3000 allowed 
accurate determination of the tumor margin just before the PDT. The 
complete remission (CR) rate following NPe6-PDT in the cases with 
early lung cancer was 93.3% (42 /45 lesions). We also conﬁrmed the 
loss of red ﬂuoresce from the tumors immediately after the PDT using 
SAFE-3000. We conﬁrmed that all the NPe6 in the tumor had been 
excited and photobleached by the laser irradiation (664 nm) and that no 
additional laser irradiation was needed for curative treatment. 
Conclusions: This novel PDD system using SAFE-3000 and NPe6 
improved the quality and efﬁcacy of PDT and avoided misjudgment of 
the dose of the photosensitizer or laser irradiation in PDT. 
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Background: Radiofrequency ablation therapy (RFA) is widely ap-
plied for the treatment thoracic malignancies as a modality of local 
control therapy lately. RFA procedure itself is thought to be almost safe. 
However, assessment of therapeutic efﬁcacy following RFA procedure 
is not well established. 
Lately, the use of FDG-PET-CT scan has been advocated for early 
tumor diagnosis or early recurrent cancer detection in the ﬁeld of 
thoracic malignancies. Although several studies showing the beneﬁt 
of FDG-PET-CT scan in RFA for thoracic malignancies have been 
reported, optimal timing of examinations after RFA, appropriate fol-
